Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Other

Richard Jiao

Lihu Yang

Sander G Mills

Changyou Zhou

Gregori J Morriello

Christopher Richard Moyes

Shankaran Kothandaraman

Alexander Pasternak

Gabor Butora

Stephen D Goble

Deodialsingh Guiadeen

Cheng Tang

The present invention is directed to compounds of the formula I: (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. The present invention is also directed to intermediates useful in the preparation of formula I compounds.

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

Compounds of Formula I: (wherein n, R, R, R, R, R, R, R, R, R, R, R, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

The present invention is directed to compounds of the formulas I and II: wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Z, l, m, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. 

Amino cyclobutylamide modulators of chemokine receptor activity

The present invention is directed to methods for treating, preventing, ameliorating, controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease, which method comprises the administration to a patient of an effective amount of the compound of formula I: (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2 

Growing community of inventors

Collingswood, NJ, United States of America

Richard Jiao